In vitro characterization of AR-A000002, a novel 5-hydroxytryptamine1B autoreceptor antagonist

被引:20
作者
Ahlgren, C
Eriksson, A
Tellefors, P
Ross, SB
Stenfors, C
Malmberg, Å [1 ]
机构
[1] AstraZeneca R&D, Dept Mol Pharmacol, Local Discovery Res Area CNS & Pain Control, S-15185 Sodertalje, Sweden
[2] AstraZeneca R&D, Dept Mol Sci, Local Discovery Res Area CNS & Pain Control, S-15185 Sodertalje, Sweden
[3] AstraZeneca R&D, Dept Gen Pharmacol, Local Discovery Res Area CNS & Pain Control, S-15185 Sodertalje, Sweden
[4] AstraZeneca R&D, Dept Biosci, Local Discovery Res Area CNS & Pain Control, S-15185 Sodertalje, Sweden
关键词
5-HT; (5-hydroxytryptamine; serotonin); 5-HT1B receptor; 5-HT1B antagonist; GR125743;
D O I
10.1016/j.ejphar.2004.07.067
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The in vitro pharmacological properties of AR-A000002 ((R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide), a novel 5-hydroxytryptamine (5-HT)(1B) receptor antagonist, were studied. AR-A000002 bound with high affinity to guinea pig cortex and recombinant guinea pig 5-HT1B receptors (K-i=0.24 and 0.47 nM) and with 10-fold lower affinity to 5-HT1D receptors. The compound displayed weak or no affinity for 63 other binding sites tested. In [S-35]GTPgammaS assays AR-A000002 showed 50% efficacy and inhibited 5-HT stimulation with 66% and a pA(2) value of 8.9. In slices of guinea pig cortex, AR-A000002 enhanced the Outflow Of [H-3]5-HT upon electrical stimulation. The compound blocked sumatriptan-evoked contraction of rabbit saphenous veins without inducing any contraction itself Thus, in these two systems AR-A000002 behaved as a 5-HT1B receptor antagonist. It is concluded that AR-A000002 is a selective high affinity 5HT(1B) receptor ligand that shows partial agonist activity in recombinant systems. In native tissues AR-A000002 behaves as a 5-HT1B receptor antagonist. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:67 / 75
页数:9
相关论文
共 34 条
[1]   Binding profile of the novel 5-HT1B/1D receptor antagonist, [H-3]GR 125,743, in guinea-pig brain: A comparison with [H-3]5-carboxamidotryptamine [J].
Audinot, V ;
Lochon, S ;
NewmanTancredi, A ;
Lavielle, G ;
Millan, MJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 327 (2-3) :247-256
[2]  
Bard JA, 1996, N-S ARCH PHARMACOL, V354, P237
[3]   LOCALIZATION OF 5-HT1B, 5-HT1D-ALPHA, 5-HT1E AND 5-HT1F, RECEPTOR MESSENGER-RNA IN RODENT AND PRIMATE BRAIN [J].
BRUINVELS, AT ;
LANDWEHRMEYER, B ;
GUSTAFSON, EL ;
DURKIN, MM ;
MENGOD, G ;
BRANCHEK, TA ;
HOYER, D ;
PALACIOS, JM .
NEUROPHARMACOLOGY, 1994, 33 (3-4) :367-386
[4]  
CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099
[5]  
DOMENECH T, 1997, NAUNYNSCHMIEDEBERS A, V356, P326
[6]   IDENTITY OF INHIBITORY PRESYNAPTIC 5-HYDROXYTRYPTAMINE (5-HT) AUTORECEPTORS IN THE RAT-BRAIN CORTEX WITH 5-HT1B BINDING-SITES [J].
ENGEL, G ;
GOTHERT, M ;
HOYER, D ;
SCHLICKER, E ;
HILLENBRAND, K .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1986, 332 (01) :1-7
[7]   LOWRY PROTEIN ASSAY CONTAINING SODIUM DODECYL-SULFATE IN MICROTITER PLATES FOR PROTEIN DETERMINATIONS ON FRACTIONS FROM BRAIN-TISSUE [J].
HARRINGTON, CR .
ANALYTICAL BIOCHEMISTRY, 1990, 186 (02) :285-287
[8]   Alignment of receptor nomenclature with the human genome: Classification of 5-HT1B and 5-HT1D receptor subtypes [J].
Hartig, PR ;
Hoyer, D ;
Humphrey, PPA ;
Martin, GR .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1996, 17 (03) :103-105
[9]   Combinatorial gene expression using multiple episomal vectors [J].
Horlick, RA ;
Schilling, AE ;
Samama, P ;
Swanson, RN ;
Fitzpatrick, VD ;
Robbins, AK ;
Damaj, B .
GENE, 2000, 243 (1-2) :187-194
[10]   SPECIES-DIFFERENCES IN THE PHARMACOLOGY OF TERMINAL 5-HT AUTORECEPTORS IN MAMMALIAN BRAIN [J].
HOYER, D ;
MIDDLEMISS, DN .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1989, 10 (04) :130-132